Physician profile
Jerry Best
NPI 1770560260
$3,318.78
in general payments reported to CMS, 2019-2025
29 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $18.07 · 2023: $543 · 2024: $1,150 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.35 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $469.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $264.90 | 2024-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $256.37 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $189.60 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $174.38 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $161.67 | 2025 | Vyepti |
| Lilly USA, LLC | $135.93 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Eisai INC. | $121.01 | 2024-2025 | |
| Boston Scientific Corporation | $106.83 | 2023-2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $98.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.46 | 2024-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $79.62 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $65.70 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $56.73 | 2023-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.45 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Xeris Pharmaceuticals, INC. | $46.92 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Corcept Therapeutics | $46.65 | 2024 | Korlym |
| Dexcom, INC. | $42.76 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $31.79 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $27.48 | 2024-2025 | Zoryve |
| Axsome Therapeutics, INC. | $25.47 | 2025 | Auvelity |
| Pulmonx Corporation | $24.78 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Novartis Pharmaceuticals Corporation | $23.08 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.42 | 2024 | Synjardy, Tradjenta, Jardiance |
| Medtronic, INC. | $17.90 | 2023 | Intellis Adaptivestim |
| Philips North America LLC | $16.17 | 2025 | Extended Holter |
| Acella Pharmaceuticals, LLC | $15.40 | 2025 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $14.58 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.